Eli Lilly and Co.

Market surge doesn't lift Lilly EndowmentRestricted Content

March 6, 2010
Kathleen McLaughlin
Lilly Endowment's resistance to diversify its holdings reached a new height last year, as it failed to sell a single share of the underperforming Eli Lilly and Co. stock while the broader market surged.
More

Three Indiana companies among world's most admired

March 5, 2010
Brightpoint, WellPoint and Cummins are recognized by Fortune magazine as being among the best in their industries.
More

Cornelius to retire as Bristol-Myers Squibb CEO

March 3, 2010
 IBJ Staff and Associated Press
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
More

To attack costs, Lilly accelerates R&D

March 3, 2010
J.K. Wall
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep getting higher for Eli Lilly and Co.'s efforts to develop drugs faster and cheaper.
More

Lilly to shift more employees to Covance

February 26, 2010
J.K. Wall
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
More

Obama health reform plan slaps drugmakers

February 24, 2010
J.K. Wall
Drugmakers, such as Indianapolis-based Eli Lilly and Co., would shoulder $3.3 billion in fees, face ban on pay-for-delay deals with generic competitor.
More

Lilly, Merck, Pfizer starting research center

February 23, 2010
Associated Press
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
More

WellPoint gets tax delay in Obama health plan

February 22, 2010
Bloomberg News
Insurers WellPoint Inc. and others would get a delay in taxes on premiums and high-cost medical benefits, along with additional funding for expanding Medicaid, under a White House proposal
More

Lilly asks shareholders to lower takeover barrier

February 20, 2010
J.K. Wall
Eli Lilly and Co. directors have recommended that shareholders toss out the drugmaker's most potent protection against unwanted takeovers: an 80-percent supermajority vote threshold for any shareholder mutiny to succeed.
More

Teva gets European OK to sell generic of Lilly's Evista

February 19, 2010
Bloomberg News
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
More

Pfizer's Viagra patent partially rejected in Lilly fight

February 16, 2010
Bloomberg News
The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn't different enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against Eli Lilly and Co. over its rival Cialis drug.
More

Lilly awards pay increases to top executives

February 8, 2010
Peter Schnitzler, J.K. Wall
Eli Lilly and Co. CEO John Lechleiter's total compensation increased $4.1 million in 2009.
More

Mississippi settles Zyprexa suit against Lilly for over $18M

February 4, 2010
Associated Press
Mississippi will receive $18.5 million from Indianapolis-based drugmaker Eli Lilly and Co. as part of a settlement over claims the company promoted the anti-psychotic Zyprexa for ailments it was not federally approved to treat.
More

Q&A: Dr. Kristine Courtney

February 3, 2010
J.K. Wall
Dr. Kristine Courtney, Eli Lilly and Co.’s senior director of corporate health services, describes how and why the company spent two years making its clinics some of the first to electronically swap patient records with a local hospital database.
More

Lilly shares trade down after fourth-quarter profits falls

January 28, 2010
J.K. Wall
Analysts worry about dive in already paltry sales of new blood thinner Effient
More

Lilly's profits fall, miss analyst expectations

January 28, 2010
J.K. Wall
The Indianapolis-based drugmaker says a weaker dollar depressed earnings in the fourth quarter compared with a year ago.
More

Lilly looks to autoimmune drugs

January 27, 2010
J.K. Wall
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune diseases: The costs of treating them are growing twice as fast as the prescription drug market.
More

Lilly shares get boost from OK of rival's drug

January 26, 2010
 IBJ Staff and Bloomberg News
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators' clearance of a similar drug.
More

Biotech firm plans $28M Greenwood plant

January 19, 2010
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to help develop a cheaper form of insulin that could gain significant market share.
More

FDA letters scold Lilly, others over marketing materials

January 13, 2010
Associated Press
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately display information about the drug's side effects.
More

FDA cancels meeting to review Lilly's Cymbalta

January 5, 2010
Associated Press
The agency said the meeting was canceled "to allow time for the FDA to review new information" about a proposed new use for the drug.
More

Ruth Lilly remembered for 'selfless' giving

December 31, 2009
Andrea Muirragui Davis
Lilly, 94, who died Wednesday, gave away hundreds of millions of dollars of her fortune during her lifetime.
More

Eli Lilly and Co. heiress Ruth Lilly dies at 94

December 31, 2009
Associated Press
Over the course of her life, the last surviving great-grandchild of pharmaceutical magnate Eli Lilly gave away much of her inheritance.
More

Corporations bet on insiders to bend reform

December 30, 2009
J.K. Wall
Indianapolis health care heavyweights are among those spending $635 million, employing 166 former aides to key congressional leaders and committees in health reform process.
More

Lilly scurries to get out from under Zyprexa cloud

December 26, 2009
J.K. Wall
Another year of rapid change at Eli Lilly and Co. did little to move the company out from under the cloud cast by its best-selling drug, Zyprexa.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am so impressed that the smoking ban FAILED in Kokomo! I might just move to your Awesome city!

  2. way to much breweries being built in indianapolis. its going to be saturated market, if not already. when is enough, enough??

  3. This house is a reminder of Hamilton County history. Its position near the interstate is significant to remember what Hamilton County was before the SUPERBROKERs, Navients, commercial parks, sprawling vinyl villages, and acres of concrete retail showed up. What's truly Wasteful is not reusing a structure that could still be useful. History isn't confined to parks and books.

  4. To compare Connor Prairie or the Zoo to a random old house is a big ridiculous. If it were any where near the level of significance there wouldn't be a major funding gap. Put a big billboard on I-69 funded by the tourism board for people to come visit this old house, and I doubt there would be any takers, since other than age there is no significance whatsoever. Clearly the tax payers of Fishers don't have a significant interest in this project, so PLEASE DON'T USE OUR VALUABLE MONEY. Government money is finite and needs to be utilized for the most efficient and productive purposes. This is far from that.

  5. I only tried it 2x and didn't think much of it both times. With the new apts plus a couple other of new developments on Guilford, I am surprised it didn't get more business. Plus you have a couple of subdivisions across the street from it. I hope Upland can keep it going. Good beer and food plus a neat environment and outdoor seating.

ADVERTISEMENT